MEM-1003(MEM-1003) - 药物靶点：L-type calcium channel x calcium channel_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

L-type calcium channel x calcium channel

作用机制

L-type calcium channel阻滞剂(L-型电压门控性钙通道家族阻滞剂)、calcium channel抑制剂(钙通道抑制剂)

治疗领域

神经系统疾病其他疾病心血管疾病

在研适应症-

非在研适应症

阿尔茨海默症躁郁症躁郁症1型+ [3]

原研机构

Bayer AG

在研机构-

非在研机构

Memory Pharmaceuticals Corp.

Bayer AG

The Stanley Medical Research Institute

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C22H25ClN2O5

InChIKeyGTIKSQYSAKETQA-UHFFFAOYSA-N

CAS号165187-25-7

关联

2

项与 MEM-1003 相关的临床试验

NCT00374920 / Completed临床2期

A Multicenter, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MEM 1003 for the Treatment of Patients With Bipolar I Disorder Suffering Acute Manic or Mixed Episodes

The purpose of this study is to establish the potential of MEM 1003 as a safe and effective treatment for patients with an acute manic or mixed episode of bipolar disorder.

开始日期2006-09-01

申办/合作机构

Memory Pharmaceuticals Corp.

[+1]

NCT00257673 / Completed临床2期

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MEM 1003 in Patients With Mild to Moderate Alzheimer's Disease

The purpose of this study is to determine in a 12-week treatment study if MEM 1003 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.

开始日期2005-11-01

申办/合作机构

Memory Pharmaceuticals Corp.

100 项与 MEM-1003 相关的临床结果

登录后查看更多信息

100 项与 MEM-1003 相关的转化医学

登录后查看更多信息

100 项与 MEM-1003 相关的专利（医药）

登录后查看更多信息

3

项与 MEM-1003 相关的文献（医药）

2011-01-01·Journal of Central Nervous System Disease

Current and Emerging Therapies for the Management of Bipolar Disorders

Article

作者: El-Mallakh, Rif S. ; Gao, Yonglin ; Elmaadawi, Ahmed Z. ; Lohano, Kavita ; Roberts, R. Jeannie

Bipolar disorder is a complex condition to treat because agents that may be effective for a specific phase may not be effective for other phases, or may even worsen the overall course of the illness. Over the last decade there has been an increase in research activity in the treatment of bipolar illness. There are now several agents that are well established for the treatment of acute mania (lithium, divalproex, carbamazepine, nearly all antipsychotics), acute bipolar depression (lamotrigine, quetiapine, olanzapine/fluoxetine combination), and relapse prevention (lithium, lamotrigine, divalproex, most second generation antipsychotics). There are also novel treatments that are being studied for all three phases. These include eslicarbazepine, cariprazine, MEM-1003, memantine, tamoxifen and pentazocine for acute mania; pramipexole, modafinil, armodafinil, divalproex, lurasidone, agomelatine, cariprazine, lisedexamfetamine, riluzole, RG-2417, bifeprunox, ropinirole, GSK1014802, and magnetic stimulation for bipolar depression; and asenapine, lurasidone, and cariprazine for relapse prevention. Additionally, there are accumulating data that antidepressants, particularly serotoninergic ones, are not particularly effective in acute bipolar depression and may worsen the course of the illness.

2007-11-01·Methods and findings in experimental and clinical pharmacology

Gateways to clinical trials.

作者: Prous, J R ; Rabasseda, X ; Bayés, M

1-Octanol, 9vPnC-MnCc; Abiraterone acetate, Adalimumab, Adefovir dipivoxil, Alemtuzumab, Aliskiren fumarate, Aminolevulinic acid hexyl ester, Amlodipine besylate/atorvastatin calcium, Amrubicin hydrochloride, Anakinra, Aripiprazole, ARRY-520, AS-1404, Asimadoline, Atazanavir sulfate, AVE-0277, Azelnidipine; Bevacizumab, Bimatoprost, Boceprevir, Bortezomib, Bosentan, Botulinum toxin type B; Certolizumab pegol, Cetuximab, Clevudine, Contusugene ladenovec, CP-751871, Crofelemer, Cypher, CYT006-AngQb; Darbepoetin alfa, Desmopressin, Dexlansoprazole, DG-041; E-5555, Ecogramostim, Entecavir, Erlotinib hydrochloride, Escitalopram oxalate, Eszopiclone, Everolimus, Ezetimibe, Ezetimibe/simvastatin; Falecalcitriol, Fampridine, Fesoterodine fumarate, Fingolimod hydrochloride; Gefitinib, Ghrelin (human), GS-7904L, GV-1001; HT-1001; Insulin detemir, ISIS-112989, Istradefylline; Laquinimod sodium, Latanoprost/timolol maleate, Lenalidomide, Levobetaxolol hydrochloride, Liposomal doxorubicin, Liposomal morphine sulfate, Lubiprostone, Lumiracoxib, LY-518674; MEM-1003, Mesna disulfide, Mipomersen sodium, MM-093, Mycophenolic acid sodium salt; Naptumomab estafenatox, Natalizumab; Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide; Paclitaxel nanoparticles, Paclitaxel poliglumex, Pasireotide, Pazufloxacin mesilate, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Peginterferon alfa-2b/ribavirin, Pegvisomant, Pemetrexed disodium, Pimagedine, Pimecrolimus, Pramlintide acetate, Prasterone, Pregabalin, Prulifloxacin; QAE-397; Rec-15/2615, RFB4(dsFv)-PE38, rhGAD65, Roflumilast, Romiplostim, Rosuvastatin calcium, Rotigotine, Rupatadine fumarate; Safinamide mesilate, SIR-Spheres, Sitagliptin phosphate, Sodium phenylacetate, Sodium phenylacetate/Sodium benzoate, Sorafenib, SSR-244738; Taribavirin hydrochloride, Taxus, Teduglutide, Tegaserod maleate, Telaprevir, Telbivudine, Tenofovir disoproxil fumarate, Tigecycline, Tiotropium bromide, Trabectedin, Travoprost, Treprostinil sodium; Ustekinumab; Valsartan/amlodipine besylate, Varenicline tartrate, Vildagliptin; Zofenopril calcium.

2007-05-01·Neurobiology of Aging2区 · 医学

Efficacy of MEM 1003, a novel calcium channel blocker, in delay and trace eyeblink conditioning in older rabbits

2区 · 医学

Article

作者: Gregory M. Rose ; Voon S. Ong ; Diana S. Woodruff-Pak

Eyeblink conditioning is a relatively simple form of associative learning that shows neurobiological and behavioral parallels across several species, including humans. Aged subjects acquire eyeblink conditioning more slowly than young ones. In addition, eyeblink conditioning effectively discriminates patients with Alzheimer's disease from healthy older adults. The present study evaluated the effect of a novel L-type Ca2+ channel antagonist, MEM 1003, on delay and trace eyeblink conditioning in older (mean 33.4 months old) female New Zealand white rabbits. In the delay conditioning paradigm, an 850 ms tone conditioning stimulus (CS) was followed 750 ms after its onset by a 100 ms corneal air puff. Several trace conditioning paradigms were evaluated, with a silent period of 300, 400 or 500 ms between the end of the tone CS and the delivery of the air puff. Learning was more difficult in the longer trace paradigms than in the delay paradigm. MEM 1003, at a dose of 2.0 mg/kg, s.c., given daily 30 min prior to training on each of the 15 training days, enhanced learning compared to vehicle injections in both delay and trace paradigms. However, higher or lower doses were ineffective. These results support previous work demonstrating that modulation of Ca2+ channel activity can reduce age-related cognitive impairments.

100 项与 MEM-1003 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
躁郁症1型	临床2期	美国	Memory Pharmaceuticals Corp.	2006-09-01
躁郁症1型	临床2期	美国	The Stanley Medical Research Institute	2006-09-01
躁狂	临床2期	美国	Memory Pharmaceuticals Corp.	2006-09-01
躁狂	临床2期	美国	The Stanley Medical Research Institute	2006-09-01
阿尔茨海默症	临床2期	-	The Stanley Medical Research Institute	-
阿尔茨海默症	临床2期	-	Bayer AG	-
阿尔茨海默症	临床2期	-	The Stanley Medical Research Institute	-
阿尔茨海默症	临床2期	-	Bayer AG	-
躁郁症	临床2期	-	Bayer AG	-
血管性痴呆	临床2期	美国	Memory Pharmaceuticals Corp.	-